Tipifarnib in the treatment of acute myeloid leukemia

Farnesyltransferase inhibitors (FTIs) are a new class of biologically active anticancer drugs. The exact anti-tumorigenic mechanism is currently unknown. FTIs inhibit farnesylation of a wide range of target proteins. In preclinical models, tipifarnib (R115777, Zarnestra®), a non-peptidomimetic competitive FTI, showed great potency against leukemic cells. Although it has recently demonstrated clinical responses in adults with refractory and relapsed acute myeloid leukemia (AML), and in older adults with newly diagnosed poor-risk AML, its activity was far less than anticipated. However, it appears that tipifarnib as a single agent may be important in selected groups of patients. Much remains to be learned to optimize such therapy in patients with AML. To this end, trials that combine tipifarnib with cytotoxics are ongoing.

• Publication year

  2007

• Venue

  Biologics : targets & therapy

• Publication date

  2007-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 19707311PMCID 2721284
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Farnesyl Transferase Inhibitors

  2008cited by this paper
• A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.

  2007cited by this paper
• A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

  2007cited by this paper
• A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

  2007cited by this paper
• Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia

  2007cited by this paper
• Age and acute myeloid leukemia.

  2006cited by this paper
• Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

  2006cited by this paper
• Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation.

  2006cited by this paper
• A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.

  2006cited by this paper
• Lipid posttranslational modifications. Farnesyl transferase inhibitors.

  2006cited by this paper
• Comparison of Survival Times after Administration of Tipifarnib or Ara-C-Containing Therapy, to Older Patients with Newly-Diagnosed Acute Myeloid Leukemia.

  2006cited by this paper
• Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

  2006cited by this paper
• Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial

  2005cited by this paper
• RRP22 is a farnesylated, nucleolar, Ras-related protein with tumor suppressor potential.

  2005cited by this paper
• Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

  2005cited by this paper
• Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

  2005cited by this paper
• The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling

  2005cited by this paper
• Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways

  2005cited by this paper
• Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.

  2005cited by this paper
• Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.

  2005cited by this paper
• Alternate Week Administration of the Farnesyltransferase Inhibitor Tipifarnib (ZARNESTRA®, R115777) in Patients with Myelodysplastic Syndrome: Results of a Phase 1 Study.

  2005cited by this paper
• Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility.

  2004cited by this paper
• Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

  2004cited by this paper
• A tagging-via-substrate technology for detection and proteomics of farnesylated proteins.

  2004cited by this paper
• Acute myeloid leukemia

  2004cited by this paper
• Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.

  2004cited by this paper
• Farnesyl Protein Transferase Inhibitors and Other Therapies Targeting the Ras Signal Transduction Pathway

  2004cited by this paper
• Cyclin B1 Is a Critical Target of RhoB in the Cell Suicide Program Triggered by Farnesyl Transferase Inhibition

  2004cited by this paper
• Tumorigenesis: Flying beneath the radar

  2004cited by this paper
• The Rheb family of GTP-binding proteins.

  2004cited by this paper
• Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.

  2004cited by this paper
• Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia

  2003cited by this paper
• Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.

  2003cited by this paper
• Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.

  2003cited by this paper
• Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.

  2003cited by this paper
• Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery.

  2003cited by this paper
• The Tyrosine Phosphatase PRL-1 Localizes to the Endoplasmic Reticulum and the Mitotic Spindle and Is Required for Normal Mitosis*

  2002cited by this paper
• Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.

  2002cited by this paper
• Farnesyltransferase inhibitors: promises and realities.

  2002cited by this paper
• RhoB Is Dispensable for Mouse Development, but It Modifies Susceptibility to Tumor Formation as Well as Cell Adhesion and Growth Factor Signaling in Transformed Cells

  2001cited by this paper
• Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

  2001cited by this paper
• Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

  2001cited by this paper
• Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

  2001cited by this paper
• Treatment of acute myelogenous leukemia in older adults

  2000cited by this paper
• Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules*

  2000cited by this paper
• Acute myelogenous leukemia and aging. Clinical interactions.

  2000cited by this paper
• Regulation of endocytic traffic by rho family GTPases.

  2000cited by this paper
• Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

  2000cited by this paper
• Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms.

  1999cited by this paper
• Acute myeloid leukemia.

  1999cited by this paper
• Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.

  1999cited by this paper
• Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

  1999cited by this paper
• Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice.

  1999cited by this paper
• Mammalian cytosolic DnaJ homologues affect the hsp70 chaperone-substrate reaction cycle, but do not interact directly with nascent or newly synthesized proteins.

  1998cited by this paper
• Activation of Phosphatidylinositol 3-Kinase Is Sufficient for Cell Cycle Entry and Promotes Cellular Changes Characteristic of Oncogenic Transformation

  1998cited by this paper
• Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells.

  1998cited by this paper
• Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment.

  1997cited by this paper
• Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I*

  1997cited by this paper
• Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.

  1997cited by this paper
• K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors*

  1997cited by this paper
• Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB*

  1997cited by this paper
• The Microtubule-dependent Motor Centromere–associated Protein E (CENP-E) Is an Integral Component of Kinetochore Corona Fibers That Link Centromeres to Spindle Microtubules

  1997cited by this paper
• Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element.

  1997cited by this paper
• Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases.

  1996cited by this paper
• CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis

  1995cited by this paper
• Transcriptional regulation by MAP kinases

  1995cited by this paper
• Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

  1995cited by this paper
• An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing.

  1994cited by this paper
• Function and regulation of ras.

  1993cited by this paper
• Proteins regulating Ras and its relatives

  1993influential reference
• Protein prenylation: key to ras function and cancer intervention?

  1992cited by this paper
• The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors.

  1992cited by this paper
• YDJ1p facilitates polypeptide translocation across different intracellular membranes by a conserved mechanism.

  1992cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• In older adults

  1980cited by this paper

• Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective.

  2025cites this paper
• Exploring the Molecular Insights of Imidazole and Benzimidazole Scaffold for Cancer Therapy: Synthesis, In-vitro Cytotoxicity and SAR Studies

  2024cites this paper
• Random walk with restart on multilayer networks: from node prioritisation to supervised link prediction and beyond

  2023cites this paper
• Glioblastoma: Current Status, Emerging Targets, and Recent Advances

  2022cites this paper
• Pharmacological Inhibition of Exosome Machinery: An Emerging Prospect in Cancer Therapeutics.

  2022cites this paper
• Universal multilayer network exploration by random walk with restart

  2021cites this paper
• A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma

  2021cites this paper
• Epigenetic modulation and apoptotic induction by a novel imidazo-benzamide derivative in human lung adenocarcinoma cells

  2021cites this paper
• Frühe Rekonstitution zirkulierender Antikörper-sezernierender Zellen nach haploidenter Stammzelltransplantation

  2020cites this paper
• Synthesis, docking studies and antitumor activity of phenanthroimidazole derivatives as promising c-myc G-quadruplex DNA stabilizers.

  2020cites this paper
• Modular micro-physiological human tumor/tissue models based on decellularized tissue for improved preclinical testing.

  2020cites this paper
• The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines

  2018cites this paper
• Pharmacogenomics of Primary Blood Cancer Cells

  2017cites this paper
• Tipifarnib prevents development of hypoxia-induced pulmonary hypertension

  2017cites this paper
• Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy.

  2017cites this paper
• Imidazoles as potential anticancer agents.

  2017cites this paper
• Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia

  2016cites this paper
• Development of drugs based on imidazole and benzimidazole bioactive heterocycles: recent advances and future directions

  2016cites this paper
• Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.

  2015cites this paper
• O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas

  2013cites this paper
• Neutrophil uptake of nitrogen-bisphosphonates leads to the suppression of human peripheral blood γδ T cells

  2013cites this paper
• Synthesis of Trypanosoma cruzi lanosterol 14α demethylase (TcCYP51) Inhibitors for the treatment of Chagas disease

  2013cites this paper
• Allium compounds, dipropyl and dimethyl thiosulfinates as antiproliferative and differentiating agents of human acute myeloid leukemia cell lines

  2008cites this paper